Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.

ABSTRACT:

Importance

In many health systems, access to off-label drug use is controlled through reimbursement restrictions by health insurers, especially for expensive cancer drugs.

Objective

To determine whether evidence from randomized clinical trials is associated with reimbursement decisions for requested off-label use of anticancer drugs in the Swiss health system.

Design, setting, and participants

This cross-sectional study used reimbursement requests from routinely collected health records of 5809 patients with drug treatment for cancer between January 2015 and July 2018 in 3 major cancer centers, covering cancer care of approximately 5% of the Swiss population, to identify off-label drug use. For each off-label use indication with 3 or more requests, randomized clinical

SUBMITTER: Herbrand AK 

PROVIDER: S-EPMC7926292 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature